8-エチル-6-(2,4-ジクロロフェニル)-2-[(4-ピペラジノ-3-フルオロフェニル)アミノ]ピリド[2,3-d]ピリミジン-7(8H)-オン

8-エチル-6-(2,4-ジクロロフェニル)-2-[(4-ピペラジノ-3-フルオロフェニル)アミノ]ピリド[2,3-d]ピリミジン-7(8H)-オン 価格

8-エチル-6-(2,4-ジクロロフェニル)-2-[(4-ピペラジノ-3-フルオロフェニル)アミノ]ピリド[2,3-d]ピリミジン-7(8H)-オン 化学特性,用途語,生産方法

• 説明

  FRAX486 is an inhibitor of group I p21-activated kinases (PAKs; IC₅₀s = 8.25, 39.5, and 55.3 nM for PAK1, PAK2, and PAK3, respectively). It is selective for group I PAKs over PAK4, a group II PAK (IC₅₀ = 779 nM). FRAX486 (20 mg/kg) reverses decreases in the mean density of apical dendritic spines in the temporal cortex in the Fmr1^-/- mouse model of fragile X syndrome. It completely abolishes audiogenic seizures, hyperactivity, and stereotypical movements in Fmr1^-/- mice when administered at a dose of 30 mg/kg. FRAX486 prevents adolescent cortical dendritic spine loss and rescues prepulse inhibition deficits in a Disc1 knockdown mouse model of schizophrenia.

• 使用

  FRAX 486 is a small-molecule PAK inhibitor. This compound has neuroprotective properties.

• Biochem/physiol Actions

  FRAX486 is a potent, group I-selective p21-activated kinase (PAK) inhibitor (PAK1/2/3 IC50 = 8.25/39.5/55.3 nM; group II PAK4 IC50 = 779 nM). FRAX486 effectively inhibits PAK-mediated PKD1 Ser203 phosphorylation and PAK1/2 Ser144/141 autophosphorylation upon angiotensin II (ANGII) stimulation of rat IEC-18 cells (IC50 ～0.5 μM) and exhibits in vivo efficacy in rescuing the autism-like phenotypes among Fmr1 knockout fragile syndrome (FXS) mice (20 mg/kg s.c.) as well as in ameliorating schizophrenia-associated dendritic spine deterioration among Disc1 knockdown mice (10 μg/g or 10 mg/kg i.p.) with good pharmacokinetic properties and blood–brain barrier (BBB) permeability.

8-エチル-6-(2,4-ジクロロフェニル)-2-[(4-ピペラジノ-3-フルオロフェニル)アミノ]ピリド[2,3-d]ピリミジン-7(8H)-オン 生産企業

Global(99)Suppliers

8-エチル-6-(2,4-ジクロロフェニル)-2-[(4-ピペラジノ-3-フルオロフェニル)アミノ]ピリド[2,3-d]ピリミジン-7(8H)-オン スペクトルデータ(¹HNMR)